Keywords: elan, sell, european, prialt, rights, eisai, irish

Elan to sell European Prialt rights to Eisai

Article | 20 February 2006

Print This

Irish biotechnology firm Elan says it has agreed to sell the rights to Prialt (ziconotide, non-opioid severe chronic pain agent) ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in